Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 8/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 7/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467308 | 0.95 | CTSL (0.49) | CA5ACTSLPSMB1CTSBCTSK | |
| SCHEMBL6062759 | 0.94 | PSMB1 (0.55) | CA5ACTSLPSMB1CTSBCTSK | |
| SCHEMBL6061832 | 0.93 | CTSL (0.52) | CTSLPSMB1CTSBCTSKCTSS | |
| SCHEMBL6467335 | 0.92 | CTSL (0.51) | CTSLPSMB1CTSBCTSKCTSS | |
| SCHEMBL6062791 | 0.92 | CTSL (0.54) | CTSLPSMB1CTSBCTSKCTSS | |
| SCHEMBL6465270 | 0.91 | MMP3 (0.52) | CTSLPSMB1CTSBCTSK | |
| SCHEMBL6466258 | 0.90 | ANPEP (0.46) | PSMB1 | |
| SCHEMBL7046087 | 0.90 | CTSL (0.49) | CTSLPSMB1CTSBCTSKCTSS | |
| SCHEMBL7043366 | 0.90 | CTSL (0.49) | CTSLPSMB1CTSBCTSKCTSS | |
| SCHEMBL7043368 | 0.90 | CTSL (0.49) | CTSLPSMB1CTSBCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CA5A 1128/4885CTSL 18/4885PSMB1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.